Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calponin-2 (CNN2)
- Target
- CNN2
- Molecular classification
- Other (Actin-binding regulatory protein/cytoskeletal protein)
01
Overview
Calponin-2 is a 33.7 kDa actin-binding regulatory protein broadly expressed in smooth muscle, fibroblasts, endothelial cells, epithelial cells, immune cells, and various cancer cells. It stabilizes actin filaments, inhibits actin-activated myosin ATPase, and modulates cell mechanics, migration, proliferation, and energy metabolism. In disease, CNN2 is implicated in cancer cell invasion, modulation of inflammation and fibrotic responses, and is upregulated in arthritic and fibrotic tissues. Though not yet targeted by approved drugs, its biological significance makes it an attractive candidate for therapeutic intervention.
- Other names
- Calponin H2Neutral calponinSmooth muscle calponinCalponin-2
02
Mechanism of action
Mechanism for potential drugs would include inhibition or modulation of the actin-binding/regulatory function to alter cell motility, contractility, inflammatory response, or proliferation
03
Biological functions
Cytoskeletal organizationRegulation of actin-myosin interaction (inhibits myosin ATPase)Smooth muscle contraction and modulationCell adhesionCell migrationCell proliferationMechanotransductionRegulation of energy metabolism (especially in kidney fibroblasts via ESR2 interaction)
04
Disease associations
Cancer (prostate, breast, pancreatic)Inflammatory arthritisChronic kidney disease and fibrosisAcute kidney injury (AKI)Vascular diseases (atherosclerosis)Other (developmental defects due to migration/proliferation deficits)
05
Safety considerations
Disruption or deletion of CNN2 can alter cell motility, affect immune response, and could impact normal tissue repair and contractilityGlobal inhibition of CNN2 may disturb cytoskeletal dynamics across multiple cell types, leading to off-target effects
06
Interacting drugs
None currently known
07
Biomarkers
Elevated CNN2 in synovial macrophages is seen in rheumatoid arthritis and correlates with disease severityIncreased CNN2 expression in developing arthritis and in fibrotic kidney tissue may serve as a disease biomarker
Beyond the preview
Go deeper on Calponin-2 (CNN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calponin-2 (CNN2).